Autopsy report · NCT04835714
A Study to Find a Safe and Effective Dose of BI 1701963 Alone and in Combination With BI 3011441 in Patients With Advanced Cancer and a Certain Mutation (Kirsten Rat Sarcoma Viral Oncogene Homologue [KRAS])
Cause of deathFunding or business
“Sponsor decision”
Life of this trial
- Ran for about 9 months before it stopped.
- 8 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1
- Sponsor
- Boehringer Ingelheim
- Sponsor type
- Industry
- Conditions
- Solid Tumors, KRAS Mutation
- Interventions
- BI 1701963; BI 3011441
- Participants
- 8
- Sites
- 4
- Countries
- Japan
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.